Please login to the form below

CSCC

This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Another is Libtayo (cemiplimab), its latecomer checkpoint inhibitor which has however the first drug in the PD-1/PD-L1 class to be approved for cutaneous squamous cell carcinoma (CSCC), a

Latest news

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

squamous cell carcinoma (CSCC). The Regeneron-partnered drug is the first drug in the checkpoint inhibitor class to get a green light in that type of skin cancer, and is also
Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

It could also provide a leap forward for Libtayo, which was approved for cutaneous squamous cell carcinoma (CSCC) in the US in 2018 and in Europe earlier this year, but is
Dupixent gains can’t keep Sanofi on a growth track

carcinoma (CSCC) in June. ... Regeneron books sales of Libtayo in the US, where it was approved for CSCC last year, and made $68m from the drug in the first half of the year.
Dupixent drives Sanofi again, but other new drugs are lagging

It is too soon to gauge the take-up of Sanofi’s new cancer immunotherapy Libtayo (cemiplimab), which has just been approved for cutaneous squamous cell carcinoma (CSCC) in Europe after
NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

CSCC is “physically and emotionally challenging, and there is a high unmet need for new treatments.”. ... NICE backing bodes well for other reimbursement decisions in Europe, but analysts don’t see the drug making a massive impact despite being on

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest from PMHub

Lucid Group make the cut for Communiqué in seven different categories.

EXCELLENCE IN MULTICHANNEL COMMUNICATIONS. ASCENT: Actioning CSCC (cutaneous squamous-cell carcinoma) Education and Navigating Treatment Pathways.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Manager - Healthcare Consultancy: Salary depending on experience

Client Services Director +, Remote or London – Leadership Opport...: Highly Competitive Salary, Bonus &Benefits

Digital project manager: Competitive

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Digital strategist: Competitive

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Digital account director: Competitive

Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...: Highly competitive salary

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

FREELANCE (Outside IR35) Opportunities for this week below!!!: Superb Day Rate

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel: Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor: Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story: Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....

Email:
Password:

Please login to the form below

CSCC

COVID-19 Updates and Daily News

Featured jobs

Quick links